166 related articles for article (PubMed ID: 3891875)
41. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
[No Abstract] [Full Text] [Related]
42. Histologic mimics of malignant melanoma.
Bsirini C; Smoller BR
Singapore Med J; 2018 Nov; 59(11):602-607. PubMed ID: 29774360
[TBL] [Abstract][Full Text] [Related]
43. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
44. [Thermographic examination of cutaneous melanocytic nevi].
Mikulska D
Ann Acad Med Stetin; 2009; 55(1):31-8; discussion 38. PubMed ID: 20349589
[TBL] [Abstract][Full Text] [Related]
45. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
Yasuda H
Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
[TBL] [Abstract][Full Text] [Related]
46. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma.
Dalton SR; Gerami P; Kolaitis NA; Charzan S; Werling R; LeBoit PE; Bastian BC
Am J Surg Pathol; 2010 Feb; 34(2):231-7. PubMed ID: 20087158
[TBL] [Abstract][Full Text] [Related]
47. Combined melanocytic nevi: histologic variants and melanoma mimics.
Baran JL; Duncan LM
Am J Surg Pathol; 2011 Oct; 35(10):1540-8. PubMed ID: 21881487
[TBL] [Abstract][Full Text] [Related]
48. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
49. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
Clark WH; Elder DE; Guerry D; Epstein MN; Greene MH; Van Horn M
Hum Pathol; 1984 Dec; 15(12):1147-65. PubMed ID: 6500548
[TBL] [Abstract][Full Text] [Related]
50. Clinical diagnosis of dysplastic melanocytic nevi. A clinicopathologic correlation.
Kelly JW; Crutcher WA; Sagebiel RW
J Am Acad Dermatol; 1986 Jun; 14(6):1044-52. PubMed ID: 3722481
[TBL] [Abstract][Full Text] [Related]
51. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
[TBL] [Abstract][Full Text] [Related]
52. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
53. Nevoid malignant melanoma.
Schmoeckel C; Castro CE; Braun-Falco O
Arch Dermatol Res; 1985; 277(5):362-9. PubMed ID: 4026378
[TBL] [Abstract][Full Text] [Related]
54. The relationship between melanocytic nevi and malignant melanoma.
Friedman RJ; Rigel DS; Heilman ER
Dermatol Clin; 1988 Apr; 6(2):249-56. PubMed ID: 3378371
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal antibody (AFH1) immunoreactive on morphologically abnormal basal melanocytes within dysplastic nevi, nevocellular nevus nests, and melanoma.
Aronson PJ; Ito K; Fukaya T; Hashimoto K; Mehregan AH
J Invest Dermatol; 1988 Apr; 90(4):452-8. PubMed ID: 3280697
[TBL] [Abstract][Full Text] [Related]
56. Reticulin and NM23 staining in the interpretation of lymph nodal nevus rests.
Kanner WA; Barry CI; Smart CN; Frishberg DP; Binder SW; Wick MR
Am J Dermatopathol; 2013 Jun; 35(4):452-7. PubMed ID: 23694823
[TBL] [Abstract][Full Text] [Related]
57. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
59. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma.
Ahmed AA; Nordlind K; Hedblad M; Lagerholm B; Schultzberg M; Lidén S
Am J Dermatopathol; 1995 Jun; 17(3):222-9. PubMed ID: 8599429
[TBL] [Abstract][Full Text] [Related]
60. [Multiple halo nevi: their differential diagnosis from malignant melanoma].
Gordeladze AS; Pavlova TA
Arkh Patol; 1990; 52(2):66-9. PubMed ID: 2353903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
